TGF-β drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (12)
Papers in which this entity is mentioned.
- Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. (2023)
- Human 3D brain organoids: steering the demolecularization of brain and neurological diseases. (2023)
- Genetic Influences on the Developing Young Brain and Risk for Neuropsychiatric Disorders. (2023)
- Most non-canonical proteins uniquely populate the proteome or immunopeptidome. (2021)
- Macrophage Polarization States in the Tumor Microenvironment. (2021)
- Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. (2020)
- Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. (2019)
- The Immune Landscape of Cancer. (2018)
- Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. (2017)
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. (2016)
- Cancer genome landscapes. (2013)
- Myeloid cells in tumor inflammation. (2012)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| tgf-β | drug | 34 | 71 |
| tgf beta | drug | 2 | 3 |